Yarbrough Capital, LLC Viking Therapeutics, Inc. Transaction History
Yarbrough Capital, LLC
- $2.58 Billion
- Q4 2024
A detailed history of Yarbrough Capital, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Yarbrough Capital, LLC holds 6,188 shares of VKTX stock, worth $184,588. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,188
Previous 6,188
-0.0%
Holding current value
$184,588
Previous $391,000
36.32%
% of portfolio
0.01%
Previous 0.02%
Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
468Shares Held
65.8MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$303 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$180 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$147 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$77.4 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$64.4 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.29B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...